Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
Merck Sharp & Dohme LLC
Johan A Maertens; Galia Rahav; Dong-Gun Lee; Alfredo Ponce-de-León; Isabel Cristina Ramírez Sánchez; Nikolay Klimko; Anne Sonet; Shariq Haider; Juan Diego Vélez; Issam Raad; Liang-Piu Koh; Meinolf Karthaus; Jianying Zhou; Ronen Ben-Ami; Mary R Motyl; Seongah Han; Anjana Grandhi; Hetty Waskin; study investigators
Department of Biostatistics, Merck & Co, Inc, Kenilworth, NJ, USA.